Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.
Valuation & Earnings
This table compares Sunshine Biopharma and Aditxt”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.08 | -$5.97 million | ($10.15) | -0.07 |
| Aditxt | $14,336.00 | 0.18 | -$41.71 million | ($100,788.35) | -0.00 |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Sunshine Biopharma and Aditxt, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Sunshine Biopharma currently has a consensus target price of $70.00, indicating a potential upside of 10,402.63%. Given Sunshine Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Sunshine Biopharma is more favorable than Aditxt.
Profitability
This table compares Sunshine Biopharma and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Volatility and Risk
Sunshine Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Sunshine Biopharma beats Aditxt on 11 of the 14 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
